You just read:

Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens

News provided by

Antabio

06 May, 2020, 07:00 BST